EICHORPublic-registry site landscape for NCT07683325, “NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease”, a Fibrostenotic Crohn's Disease study sponsored by Agomab Spain S.L.U.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07683325 (registry record) |
| Study title | NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease |
| Official title | A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients With Fibrostenosing Crohn's Disease |
| Sponsor | Agomab Spain S.L.U. |
| Condition(s) | Fibrostenotic Crohn's Disease |
| Phase | PHASE2 |
| Listed sites | 0 |
| Intervention(s) | Ontunisertib, Placebo |
Patient-friendly overview of this study: eichor.com/study/NCT07683325.
Eichor generates a preliminary site-risk snapshot for NCT07683325 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
← Eichor home · All tracked trials · Fibrostenotic Crohn's Disease studies · Weekly briefs
